Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Identification of annexin a4 as cisplatin-susceptibility related protein in malignant mesothelioma

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Poster
  • By: NAGANO, Kazuya (National Institute of Biomedical Innovation, Laboratory of Biopharmaceutical Research, Osaka, Japan)
  • Co-author(s): Yamashita, Takuya (National Institute of Biomedical Innovation, Osaka, Japan)
    Inoue, Masaki (National Institute of Biomedical Innovation, Osaka, Japan)
    Higashisaka, Kazuma (Osaka University, Osaka, Japan)
    Yoshioka, Yasuo (Osaka University, Osaka, Japan)
    Abe, Yasuhiro (National Institute of Biomedical Innovation, Osaka, Japan)
    Mukai, Yohei (National Institute of Biomedical Innovation, Osaka, Japan)
    Kamada, Haruhiko (National Institute of Biomedical Innovation, Osaka, Japan)
    Tsutsumi, Yasuo (Osaka University, Osaka, Japan)
    Tsunoda, Shin-Ichi (National Institute of Biomedical Innovation, Osaka, Japan)
  • Abstract:

    Introduction
    Cisplatin (CDDP) is a highly effective drug for malignant mesothelioma. However, its response rate is only 20%. For this reason, it is important to elucidate the molecular mechanism of CDDP- susceptibility and to distinguish responders from non-responders. Here, in order to identify proteins related to CDDP-susceptibility, we..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses